Delivery Order SPE2DB22D3102-SPE2DB25FL2NR
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,984.25 for 100-unit vials of Xeomin on July 28, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract, which carries no set-aside designation, will be performed in Conshohocken, Pennsylvania, where the vendor maintains its corporate headquarters. Xeomin is a botulinum toxin product used for therapeutic and cosmetic applications, and this delivery order represents a...
- The Defense Logistics Agency awarded a $12,851.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. The contract, awarded on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX). The company...
- The Defense Logistics Agency awarded a delivery order valued at $5,587.40 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on August 14, 2025, with completion targeted for September 5, 2025, represents a non-competitive set-aside award drawn from a larger contract vehicle. The product will be performed and delivered from AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $11,174.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Xeomin 200 Unit Vials, with completion scheduled for August 8, 2025. This competitively awarded contract, issued without set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a $6,704.88 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin injection used in medical and therapeutic applications. This firm fixed price delivery order, issued on August 7, 2025, represents a competitively awarded, non-set-aside contract with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $1,215.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 50-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This non-set-aside contract was competitively awarded with an ultimate completion date of August 28, 2025, and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a $1,396.85 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed price delivery order, issued on July 24, 2025, with an ultimate completion date of August 14, 2025, will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $14,806.61 by the Defense Logistics Agency's Medical Supply Chain on July 31, 2025, for the supply of XEOMIN 100 UT vials. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 27, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is...
- The Defense Logistics Agency awarded a $22,349.60 firm fixed price delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This non-set-aside contract, issued on August 14, 2025, with an ultimate completion date of September 5, 2025, represents a routine pharmaceutical supply transaction fulfilling federal medical procurement needs. The award is being performed at AmerisourceBergen's corporate office...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 23, 2025, for the supply of Xeomin 100 unit vials. The contract is valued at $2,793.70 and carries a firm fixed price structure with an ultimate completion date of August 13, 2025. This non-set-aside award represents a competitive procurement action and will be performed at the contractor's Conshohocken facility....
- SPE2DB22D3102Indefinite Delivery Contract
- SPE2DB22D3102-SPE2DB25FL2NRDelivery Order
AmerisourceBergen Drug Corp received a $13,409.76 delivery order from the Defense Logistics Agency (DLA) on August 12, 2025, for the supply of Xeomin 200 Unit Vials, with completion scheduled for September 3, 2025. This firm fixed price contract award was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Xeomin is a botulinum toxin product used in medical and therapeutic applications, and this delivery order represents a discrete fulfillment under AmerisourceBergen's broader pharmaceutical supply agreements with the federal government. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a prime pharmaceutical vendor for the DLA Medical Supply Chain, AmerisourceBergen serves critical federal healthcare needs including the Defense Health Agency, U.S. Coast Guard, and other government medical systems. The company's role as a major pharmaceutical distributor enables it to fulfill diverse medical procurement requirements across multiple therapeutic domains, supporting military and veteran healthcare systems worldwide through competitively awarded contracts with consistent firm fixed pricing structures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.4k | 8/12/25 |